Peer-reviewed veterinary case report
Chemotherapy with bleomycin and cytosine arabinoside for dogs
By Batschinski, Karen et al.·Published in Journal of the American Animal Hospital Association·2018·Department of Pathology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Combination of Bleomycin and Cytosine Arabinoside Chemotherapy for Relapsed Canine Lymphoma.
- Species:
- dog
Plain-English summary
A group of dogs with relapsed lymphoma (a type of cancer) was treated with a combination of two chemotherapy drugs, bleomycin and cytosine arabinoside, to see if it could help them after previous treatments failed. Out of 19 dogs that were monitored, about 37% showed some improvement, but the average time before the cancer progressed again was just 15 days. Some dogs experienced serious side effects, including low platelet and white blood cell counts. Overall, this treatment had limited success as a rescue option for dogs that had already been treated for lymphoma.
People also search for: dog lymphoma treatment options · chemotherapy side effects in dogs · relapsed lymphoma in dogs treatment
Abstract
A retrospective study was performed to evaluate response rate, time to progression, and toxicity of a bleomycin and cytosine arabinoside (Bleo/Cytarabine) combination protocol for dogs with relapsed lymphoma (LSA). Dogs diagnosed with LSA and previously treated with chemotherapy were included in the study. A total of 20 dogs met the inclusion criteria, and 19 were evaluable for response. Bleomycin was administered subcutaneously on days 1 and 8 and cytosine arabinoside was administered subcutaneously on days 1-5 of a 21-day cycle. The median number of chemotherapy drugs given prior to the administration of Bleo/Cytarabine was 8.5. A total of 23 cycles of Bleo/Cytarabine were administered. The overall response rate was 36.8% (7 of 19 dogs had a partial response). The median time to progression was 15 days. Three dogs developed grade 3 thrombocytopenia and one dog had a grade 4 neutropenia. Bleo/Cytarabine had minor activity when used as a rescue therapy for pretreated LSA patients.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29558212/